Merit Medical downgraded by Canaccord Genuity with a new price target
$MMSI
Medical/Dental Instruments
Health Care
Canaccord Genuity downgraded Merit Medical from Buy to Hold and set a new price target of $72.00 from $73.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/28/2025 | $120.00 | Overweight | Analyst |
| 12/11/2024 | $103.00 → $120.00 | Equal Weight → Overweight | Wells Fargo |
| 6/28/2024 | $96.00 | Outperform | Robert W. Baird |
| 4/11/2024 | $88.00 | Buy | CL King |
| 2/7/2024 | $87.00 | Neutral | BofA Securities |
| 12/21/2023 | $100.00 | Hold → Buy | Canaccord Genuity |
| 12/20/2022 | $73.00 → $72.00 | Buy → Hold | Canaccord Genuity |
| 2/25/2022 | $73.00 → $72.00 | Outperform | Raymond James |
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
144 - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
10-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00
Wells Fargo upgraded Merit Medical from Equal Weight to Overweight and set a new price target of $120.00 from $103.00 previously
Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r
SOUTH JORDAN, Utah, March 27, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today that the American Society for Gastrointestinal Endoscopy (ASGE) updated its guideline on the diagnosis and management of gastroesophageal reflux disease (GERD) to include Transoral Incisionless Fundoplication (TIF 2.0) and TIF 2.0 Consecutive Transoral Incisionless Fundoplication (cTIF)* procedures as evidence-based approaches to care. GERD occurs when stomach acid flows into the esophagus, causing irritation of the tissue lining. Uncomfortable symptoms can include heartburn, upper stomach or chest pain, trouble swallowing, and chronic
At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target lesion primary patency and access circuit primary patency, respectively. SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial are scheduled for publication in the April issue of Kidney International. Twelve-month results from the randomized arm of the WAVE trial are scheduled for prese
SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on Wednesday, March 19, 2025. The ceremony begins at 9:15 A.M. (EDT) and the bell ringing takes place at 9:30 A.M. "Merit's listing on Nasdaq for 35 years marks a significant milestone in our company's history," said Lampropoulos. "Nasdaq has been an exceptional partner, providing Merit with strong execution and visibility within the investor community. We extend our sincere appreciation for Nasdaq's on-goin
Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectivelyGAAP operating margin of 10.3%, compared to 10.4% in prior year periodNon-GAAP operating margin* of 19.6%, compared to 16.6% in prior year periodGAAP EPS $0.46, down 2.6%,Non-GAAP EPS* $0.93, up 25.8%, andFree cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue of $1.357 billion, up 7.9%Constant currency revenue* and constant currency revenue, organic* up 8.5% and up 6.0%, respectivelyGAAP operating margin of 11.5 %, compared to 9.9% in prior yearNon-GAAP opera
2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the heading "Non-GAAP Financial Measure" below. SOUTH JORDAN, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of hea
Unique cell-impermeable1 design extends life-saving treatment for dialysis patientsMerit to host a WRAPSODY informational call on January 28, 2025 SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, Merit can begin commercialization of the device in the USA in 2025. WRAPSODY is designed to extend long-term vessel patency in dialysis patients2. Many patients undergoing dialysis rely on a vascular acce
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI
SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven
Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit